Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had received 2016 Technology Achievement Award (Ministry of Economic Affairs), now get 2017 Taipei Biotech Award_ Technology Transfer Gold Medal Award (Taipei City Government). T-1201 is a noval anti-tumor drug deliver system, that with intellectual property cover the top 10 medical countries. The development of T-1201 has open a new way for cancer treatment, and may bring the developing of anti-cancer agent with a new strategy. |
![T-1201-台北生技獎技轉金獎-圖-1 T-1201-台北生技獎技轉金獎-圖-1](https://www.taivex.com/wp-content/uploads/elementor/thumbs/T-1201-台北生技獎技轉金獎-圖-1-pzvinun844r5a8b7uwabh7rk3rlmzt4btxw63eiuve.jpg)
![T-1201技轉自國家衛生研究院-2 T-1201技轉自國家衛生研究院-2](https://www.taivex.com/wp-content/uploads/elementor/thumbs/T-1201技轉自國家衛生研究院-2-pzvinyekvgwako5r8xwtr6tehb33ulj96gi40ida6i.jpg)